Dubai: The Emirates Drug Establishment (EDE) has announced the registration of Blenrep (Belantamab Mafodotin) as an ...

GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products. The group posted £6. ...

That includes turnaround data for Blenrep (belantamab mafodotin), an anti-BCMA drug once thought to have been all but defunct, but which is now poised for a renaissance in blood cancer multiple ...

GSK (NYSE:GSK) announced on Monday that the U.S. FDA has granted priority review for its marketing application, aimed at ...